SpringWorks Therapeutics’ FDA Approval Fuels Investor Optimism
by Chris Cotton Update: 11.29.2023 Catapult is closing out its buy recommendation. Opened 11.28.2023 $24.14 – closed 11.29.2023 $26.90 : 11% return Introduction The recent FDA approval of OGSIVEO by…